Aims: To evaluate the therapeutic effects of n-butylidenephthalide (BP) in SOD1 G93A mouse model of amyotrophic lateral sclerosis and explore the possible mechanisms.
therapy may also provide some benefits to some of the clinical symptoms of patients with ALS, such as easing the pain, delaying the loss of strength, and preventing the complications. Additionally, although a few novel therapeutic strategies such as cell and gene therapy have been tested for the better treatment of ALS, there are still no definitive and conclusive outcome yet. [7] [8] [9] Riluzole, the only drug approved by Food and Drug Administration (FDA) of United States, can moderately prolong ALS patients' life span by 2-3 months through the inhibition of the glutamate release, but it may only benefit a subset of patients with ALS. 10, 11 Thus, it is indispensable to develop novel therapeutic drugs for this devastating disease.
n-butylidenephthalide (BP) is one of the main components derived from the volatile oil of Danggui (also referred as Angelica sinensis) which is widely used in the composite formula to treat gynecological disease and cardiovascular disease as a traditional Chinese medicine. 12, 13 BP has been reported to have multiple pharmacological effects including antitumor, anti-angina, anti-atherosclerosis, and antiplatelet agglutination activities. [14] [15] [16] As for neurodegenerative diseases, BP has been found to exert anti-apoptosis, anti-inflammation, and neuroprotective effects in the models of Parkinson's disease and Alzheimer's disease. 17, 18 Recently, BP has been tested in SOD1 G93A mouse model of ALS to show some neuroprotective effects. 19 However, the detailed molecular mechanisms for its neuroprotective impacts are still not fully demonstrated. In addition, dl-3-n-butylphthalide, one chemical analogue sharing similar chemical structure with BP, has been recently reported to exert antineuroinflammation activity and may have neuroprotective effects in SOD G93A mouse model of ALS. 20, 21 In this study, we used SOD1 G93A mouse model of ALS to systematically investigate the neuroprotective properties of BP and to explore its possible underlying mechanisms.
| MATERIALS AND METHODS

| Animals and treatments
Transgenic mice carrying mutant human SOD1 with a substitution of glycine to alanine in position 93 (SOD1 G93A ) develop a neuromuscular disease very similar to human ALS with the clinical phenotypes and histopathological features. SOD1 G93A mice have been widely used in ALS research. 22 We purchased the SOD1 G93A mice from Jackson laboratory (B6SJL-Tg-SOD1*G93A-1Gur/J, stock no. 002726). The colony was maintained by breeding transgenic male mice to wildtype (WT) females from the same background. The genotypes of offspring were determined by PCR of DNA extracted from tail tissues according to our previous protocol. 23 All experiments and animals care procedures were conducted in accordance with the Laboratory Probability of survival Disease duration (d)
60 to 160 days of age. Animal's body weight was recorded every 2 days. In addition, the rest half of SOD1 G93A mice and WT littermates were also treated from 60 days of age and sacrificed at the age of 120 days. After treatments, five mice of each group were perfused with paraformaldehyde (PFA) for histological analysis of the spinal cords, and the rest of animals were used to obtain fresh muscles and spinal cords.
| Rotarod test
The disease onset of SOD1 G93A mice was assessed by rotarod test.
From the age of 63 days, the mice were subjected to a 7-day training session (5 min/day) to adapt to the rotarod test apparatus (4 cm diameter, 20 rpm). Starting from 70 days of age, the rotarod test was performed with three trials (5 min/trial) every day. The behavioral performance was qualitatively recorded to check whether the ALS mice could complete one of all three 5-minute trials. When the animal could not insist for 5 minutes on the apparatus for all three trials, a "×"
(but not the exact duration) will be recorded to characterize the disease onset. As described in our previous studies, 23, 24 once the mouse could not complete all three trials, we considered it as the disease onset.
| Grip strength test
The hindlimb grip strength was measured at the age of 90 and 120 days. The hindlimb of mice caught the grasping force flatbed when their forelimb griped the steel wire nets. The measurements were recorded when the hindlimb separated from the flatbed by pulling their tails, and they were repeated for three times and the highest numerical record was taken.
| Assessment of life span
The life span was determined as the duration between the day of birth and the day of death that was defined as an animal's inability to right itself within 30 seconds after being placed on its back. 25 The age of death was recorded for the assessment of life span.
| Nissl staining
Mice were anesthetized with chloral hydrate and given transcardiac perfusion firstly by cold 100 mmol/L phosphate buffered saline (PBS, PH 7.4) and then by 4% PFA at the age of 120 days. The spinal cords were removed and postfixed in 4% PFA overnight at 4°C.
The tissues were then transferred to 15% and 30% sucrose dissolved in PBS, respectively, for 24 hours to be embedded by optimal cutting temperature (OCT). The embedded lumbar spinal cords (L4-L5)
were sectioned to 10 μm thickness with a Leica cryostat and frozen at −80°C until needed. Every forth section from 200 slices of each mouse was selected for Nissl staining. After being stained by 1% cresyl violet (Sigma, C5042, Saint Louis, MO, USA) for 10 minutes, the slices were dehydrated in gradient alcohol and cleared in xylol.
Sample slides were observed and photographed with a microscope (Olympus, BX51, Tokyo, Japan). The motor neurons in the anterior horns of both sides were counted by a technician who was blind to the experimental design and animals grouping. The counting criteria was as follows: (i) the motor neurons in anterior horns and before the central canal; (ii) the neurons with a maximum diameter>20 μm; (iii) the neurons with a distinct nucleus. 26 The average number of motor neurons was calculated based on 250 slices from five mice in each group.
| Immunofluorescent staining
The spinal cords for immunofluorescent staining were obtained at the age of 120 days. The sections mounted on gelatin-coated slides were roasted at 55°C and washed in PBS for three times. 
| Western blot
The acquired fresh spinal cords at the age of 120 days were lysed 
| Histopathology of skeletal muscles
After PBS perfusion, at the age of 120 days, the fresh gastrocnemius muscles (5×5×10 mm Figure 1B , while body weight loss can be easily observed during disease progression in three groups of SOD1 G93A mice, the body weight of WT mice was gradually increased.
| Statistical analysis
In addition, compared with those vehicle-treated SOD1 G93A mice, the BP treatment significantly ameliorated body weight loss.
Moreover, the rotarod test was conducted to identify the disease onset. As shown in Figure 1C , 
| Effects of BP on motor neuron survival and apoptosis
The Nissl staining was performed to investigate the effects of BP on the motor neuron survival in SOD1 G93A mice ( Figure 2A ). As shown in Figure 2B , there were fewer motor neurons in the anterior horn Figure 2B ). These results suggested that BP administration significantly ameliorated the motor neurons loss and further indicated a better neuroprotective activity than riluzole.
We then examined the effects of BP on apoptosis by immunoblot- 
| Effects of BP on neuroinflammation
Inflammatory responses and glial cells activation have been reported to be accompanied by motor neuron degeneration in ALS animal models and patients. 27 Here, we used Iba-1 and GFAP immunostainings to detect the activation of microglia and astrocytes, respectively. As shown in Figure 3A , the immunofluorescence staining indicated that the microglia and astrocytes were highly activated in vehicle-treated SOD1 G93A mice compared with their WT littermates. The BP and riluzole treatment significantly ameliorated the activation of microglia and astrocyte ( Figure 3A-C) .
The data from Western blot analysis further demonstrated that vehicle-treated SOD1 G93A mice showed higher levels of iNOS and TNF-α, two inflammatory markers, than WT mice, while these changes can be significantly suppressed by BP treatment ( Figure 3D -F).
| Effects of BP on hindlimb grip strength and histopathology of gastrocnemius muscles
As shown in Figure 4A , the hindlimb grip strength of all SOD1 The structures and function of muscles fibers apparently changed in the vehicle-treated SOD1 G93A mice as compared with WT mice.
H&E staining showed the typical atrophic features of gastrocnemius muscles such as atrophic fibers, central nuclei, and hematoxylin inclusions in the vehicle-treated SOD1 G93A mice ( Figure 4C ). BP and riluzole administration ameliorated the atrophy of muscles, as evidenced by larger myofiber, less central nuclei, and less aggregated nucleus in BP-and riluzole-treated SOD1 G93A mice than vehicle-treated SOD1 G93A mice ( Figure 4C ). Figure 4E showed that the fiber area of BP-treated SOD1 G93A mice was significantly larger than both vehicleand riluzole-treated SOD1 G93A mice (P<.05). The oxidative metabolism of muscles can be visualized by NADH staining (dark blue). As shown in Figure 4D , there were more dark blue areas and grouped myofibers in the vehicle-treated SOD1 G93A mice than WT mice. The dark blue areas and grouped myofibers in BP-and riluzole-treated SOD1 Furthermore, we measured MDA content to identify the oxidative stress level in the muscle of SOD1 G93A mice and the possible effect of BP. Consistent with NADH staining, as shown in Figure 4B, Figure 4B ).
| Effects of BP on autophagy
To investigate the effect of BP treatment on autophagy, we examined the expression levels of LC3-II, Beclin-1, and P62 ( Figure 5A ).
The quantitative analysis of Western blot bands showed that the expression levels of LC3-II ( Figure 5B ), P62 ( Figure 5C ), and Beclin-1 ( Figure 5D ) in vehicle-treated SOD1 G93A mice were significantly in- 
| DISCUSSION
Our present data showed that BP treatment could slow disease progression, prolong the life span, and extend disease duration in It has been reported that BP possesses multiple pharmacological properties against several neurological and non-neurological diseases, and it seems that its regulation on autophagy is only part of protective actions against ALS pathologies.
19 Thus, in this study, we have further investigated several possible neuroprotective mechanisms of BP on ALS.
The motor neuron degeneration of the spinal cord is the main feature of ALS. Therefore, it is very important to determine whether any treatment for ALS can prevent motor neuron loss. We found that BP treatment significantly attenuated motor neuron loss in the spinal cord of SOD1 G93A mice. Accumulating evidences support the motor neuron degeneration is partially mediated by the activation of apoptosis, which is an ongoing process and a contributor to the pathogenesis of ALS. 24, 28, 29 We measured the apoptosis level by detecting the expression of apoptosis-related proteins and by TUNEL staining. As expected, SOD1 G93A mice at the age of 120 days showed increased levels of cleaved caspase-3, pro-apoptotic protein Bax and cleaved PARP, and a decreased level of antiapoptotic protein Bcl-2, together with the increased apoptotic motor neurons in the lumbar spinal cords.
Previous study reported that BP can protect against dopaminergic Inflammatory response is considered to be related with ALS pathogenesis. 27 The expression levels of iNOS and TNF-α usually increase in the spinal cord of SOD1 G93A mouse model of ALS. 24, 36 iNOS is the marker of macrophage activation while TNF-α plays an essential role in inflammatory response. In the same way, we found the activation of microglia and astrocytes increased greatly in the anterior horn of spinal cords of vehicle-treated SOD1 G93A mice, but not in WT mice. In addition, the levels of inflammatory factors such as iNOS and TNF-α were elevated in vehicle-treated SOD1 G93A mice than WT mice.
Previous study reported that dl-3-n-butylphthalide, one chemical analogue of BP, exerted its neuroprotective effects by reducing the activation of microglia and astrocytes to inhibit the inflammation response. 21 BP can provide neuroprotective effect by inhibiting the release of various proinflammatory molecules and suppressing microglial activation. 37 Consistent with these previous findings, in the present study, we found that both the activation of glial cells and the levels of inflammation-related factors (iNOS and TNF-α) could be significantly suppressed by BP treatment. BP treatment may attenuate the inflammation response by suppressing the nuclear factor κB pathway. It may directly decrease the activity of inhibitor of nuclear factor κB (IKK), which downregulates the activation of NF-κB signal pathway.
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Muscle atrophy is another important feature in ALS. Consistent with previous studies, our data demonstrated that SOD1 G93A mice exhibited atrophic myofibers, central nuclei, and hematoxylin inclusions in gastrocnemius muscles. 23, 24 Our data further showed that BP treatment not only ameliorated the atrophy but also restored the muscular function (elevating the hindlimb grip strength). NADH staining is usually applied to evaluate the muscle metabolic pattern.
The type I fibers relying on the oxidative metabolism have the dark staining of NADH, while type II fibers relying on the glycolytic metabolism have the light staining. 39, 40 In ALS, the type II fibers tend to either atrophy or convert to the type I fibers. Here, we found that BP treatment inhibited the trend of transition from "type II" to "type I" as evidenced by attenuating the dark staining of NADH in the gastrocnemius muscles of the ALS mice. Consistent with previous reports in which BP can protect cells against oxidative stress, our present study found that BP treatment reversed the high level of MDA production in the spinal cords of ALS mice, indicating an increased level of reactive oxygen species. 41, 42 Therefore, BP may protect cells against oxidative stress by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, 41 which participates in the transcription activation of many antioxidative genes, such as SOD1, quinone 1, and NADH dehydrogenase.
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More and more evidences have suggested that autophagy plays an important role in ALS pathogenesis. Autophagy-lysosome system is one of the major systems participates in the intracellular protein degradation. 43 The mutant SOD1 protein accumulation can activate autophagy in SOD1 G93A mice. 44 Our previous study demonstrated that the LC3-II and P62 expressions were increased in the spinal cords of SOD1 G93A mice, suggesting the activation of autophagy in ALS model. 45 Recently, Hsueh et al. also reported the therapeutic potential of BP in SOD1 G93A mice possibly via a down-regulated autophagy.
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In the present study, we found that the levels of LC3-II, Beclin-1, and P62 were significantly decreased in BP-treated SOD1 G93A mice, while the levels of p-AKT, p-mTOR, and p-p70 were increased as compared with vehicle-treated SOD1 G93A mice, suggesting that BP could inhibit autophagy through AKT/mTOR signaling pathway.
In conclusion, our data support the therapeutic potential of BP for ALS. BP could slow the disease progression, prolong the life span, and extend disease duration in SOD1 G93A mouse model of ALS. BP could reduce the motor neuron loss, attenuate the muscles atrophy, and restore the gastrocnemius muscles function. Collectively, the therapeutic effects of BP may be resulted from its antiapoptosis, antiinflammation, antioxidative stress activities, as well as its inhibition on mTOR-dependent autophagy.
